Idiopathic Pulmonary Fibrosis Treatment Market Size and Forecast (2020–2030), Global and Regional Share, Trend, and Growth Opportunity Analysis
Coverage: Drug Type (Nintedanib, Pirfenidone, and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)
Avail Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00005557/
Growing Burden of Idiopathic Pulmonary Fibrosis Fuels Idiopathic Pulmonary Fibrosis Treatment Market Growth
According to data from the American Lung Association, updated in November 2022, approximately 50,000 new cases of idiopathic pulmonary fibrosis are diagnosed in the US each year. Symptoms of this condition are more noticeable in patients of age 50–70. According to an article published in the British Medical Journal in September 2022, the estimated prevalence of idiopathic pulmonary fibrosis in specialized care units in 2021 was 36.0 per 100,000. The number of patients suffering from idiopathic pulmonary fibrosis is increasing worldwide due to common risk factors such as aging, obesity, high blood pressure (hypertension), or family history, and the condition is becoming a significant socioeconomic burden for economies. Therefore, the increasing number of patients with idiopathic pulmonary fibrosis propels bolsters the fibrotic disease treatment market growth.
Drug Type -Based Insights
Based on drug type, the idiopathic pulmonary fibrosis treatment market is segmented into nintedanib, pirfenidone, and others. The nintedanib segment held a larger market share in 2022. The others segment is anticipated to register a higher CAGR of 46.3% during 2022–2030. Pirfenidone and nintedanib are the popular medicines prescribed to treat fibrotic diseases.
Distribution Channel -Based Insights
By distribution channel, the global idiopathic pulmonary fibrosis treatment market is categorized into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital pharmacies segment held the largest market share in 2022. The online pharmacies segment is anticipated to register the highest CAGR of 17.4% during 2022–2030.
About Us:
The Insight Partners is a market research solution and consultation company. Specializing in syndicate market research, our team helps clients in their hunt for revenue pockets in several industries. A team of 250+ research experts is dedicated to offering the most relevant, data-driven, and trustworthy market insights and consultation.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us
The Insight Partners
Phone: +1-646-491-9876
E-mail: [email protected]